Actively Recruiting
Evaluation of HMPL-A830 Safety, Dosing, and Preliminary Effects in Adults with Advanced Solid Tumors
Led by Hutchmed · Updated on 2026-10-01
147
Participants Needed
14
Research Sites
29 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a first-in-human, multicenter, open-label phase IIIa clinical trial to study HMPL-A830 in adults with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors who have not responded or progressed after standard treatments. The study aims to evaluate the safety, tolerability, and determine appropriate dosing of HMPL-A830, as well as explore its preliminary efficacy in selected solid tumors. The trial has two parts Part A Dose Escalation where approximately 57 participants will receive HMPL-A830 at six predefined dose levels to establish the maximum tolerated dose and recommended dose for optimization. Part B Dose Optimization will enroll about 90 participants randomized 11 to receive HMPL-A830 at two recommended dose levels stratified by tumor types, to further assess safety, tolerability, and preliminary efficacy. Participants will be closely monitored for dose-limiting toxicities, treatment-emergent adverse events, and tumor response measured by objective response rate and disease control rate. Pharmacokinetics and immunogenicity assessments will be conducted over approximately 2 years. The study includes ongoing safety and efficacy evaluations, with participation extending up to the study completion in late 2029.
CONDITIONS
Brief Title
HMPL-A830 in Solid Tumors
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here